A Sequential Study of Plasma Histidine-Rich Glycoprotein and Plasminogen in Patients with Acute Myocardial Infarction and Deep Vein Thrombosis

Jørgen Jespersen; Jørgen Gram; Elsa Bach

doi:10.1055/s-0038-1661030

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1984; 51(01): 099-102
DOI: 10.1055/s-0038-1661030

Original Article

Schattauer GmbH Stuttgart

A Sequential Study of Plasma Histidine-Rich Glycoprotein and Plasminogen in Patients with Acute Myocardial Infarction and Deep Vein Thrombosis

Jørgen Jespersen

The Section of Coagulation and Fibrinolysis, Department of Clinical Chemistry, Ribe County Hospital in Esbjerg, Esbjerg, and the Danish Institute for Clinical Epidemiology, Copenhagen, Denmark

,

Jørgen Gram

The Section of Coagulation and Fibrinolysis, Department of Clinical Chemistry, Ribe County Hospital in Esbjerg, Esbjerg, and the Danish Institute for Clinical Epidemiology, Copenhagen, Denmark

,

Elsa Bach

The Section of Coagulation and Fibrinolysis, Department of Clinical Chemistry, Ribe County Hospital in Esbjerg, Esbjerg, and the Danish Institute for Clinical Epidemiology, Copenhagen, Denmark

› Author Affiliations

Abstract

PDF Download

Summary

In a prospective study of deep vein thrombosis (DVT), detected by the Tc-plasmin test, in 34 patients with acute myocardial infarction sequential determinations were made in plasma by immunologic methods of histidine-rich glycoprotein (HRG) and total plasminogen and the concentrations of free plasminogen calculated. Mean plasma HRG concentrations were consistently higher in the group of patients, in which Tc-plasmin scanning had revealed the existence of DVT. The effect of HRG caused the level of free plasminogen to be only 50–60% of the level of total plasminogen. Fluctuations of HRG caused only minor changes in free plasminogen concentrations. Our data suggest that HRG acts as a weak, negative acute phase reactant.

Key Words

Histidine-rich glycoprotein - Plasminogen - Free plasminogen - Myocardial infarction - Deep vein thrombosis - ^99mTc-plasmin scanning

PDF (280 kb)

References

References
1 Jespersen J, Gram J, Christensen L, Astrup T. Detection of deep vein thrombosis following myocardial infarction by the technetium-99m- plasmin test. Nucl Med Commun 1983; 4: 194-203
2 Murray TS, Lorimer AR, Cox FC, Lawrie TD V. Leg-vein thrombosis following myocardial infarction. Lancet 1970; 2: 792-793
3 Maurer BJ, Wray R, Schillingford JP. Frequency of venous thrombosis after myocardial infarction. Lancet 1971; 2: 1385-1387
4 Nicolaides AN, Kakkar VV, Renney JT Q, Kinder PH, Hutchison DC S, Clarke MB. Myocardial infarction and deep-vein thrombosis. Br Med J 1971; 1: 432-434
5 Astrup T, Jespersen J. Thrombosis, disseminated intravascular coagulation, and the dynamic haemostatic balance. Aspects of prophylaxis and treatment. Inter Angio (in press).
6 Nilsson IM. Phenformin and ethylestrenol in recurrent venous thrombosis. In: Progress in chemical fibrinolysis and thrombosis. Davidson JF, Samama MM, Desnoyers PC. eds Raven Press; New York: 1975. pp 1-12
7 Heimburger N, Haupt H, Kranz T, Bauder S. Humanserumproteine mit hoher Affinität zu Carboxymethylcellulose. II. Physikalischchemische und immunologische Charakterisierung eines histidine- reichen 3.8 S-α₂-Glycoproteins (CM-protein I). Hoppe-Seyler’s Z Physiol Chem 1972; 353: 1133-1140
8 Lijnen HR, Hoylaerts M, Collen D. Isolation and characterization of human plasma protein with affinity for lysine binding sites in plasminogen. J Biol Chem 1980; 225: 10214-10222
9 Persson RB, Darte L. Labeling plasmin with technetium-99m for scintigraphic localization of thrombi. Int J Appl Radiat Isot 1977; 28: 97-104
10 Olsson CG, Albrechtsson U, Darte L, Persson RB R. Tc-99m-plasmin for rapid detection of deep vein thrombosis. Nucl Med Commun 1982; 3: 41-52
11 Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 1965; 2: 235-240
12 Jespersen J, Kluft C. Decreased levels of histidine-rich glycoprotein (HRG) and increased levels of free plasminogen in women on oral contraceptives low in estrogen. Thromb Haemostas 1982; 48: 283-285
13 Rákóczi I, Wiman B, Collen D. On the biological significance of the specific interaction between fibrin, plasminogen and antiplasmin. Biochim Biophys Acta 1978; 540: 295-300
14 Aoki N, Moroi M, Tachiya K. Effects of α₂-plasmin inhibitor on fibrin clot lysis. Its comparison with α₂-macroglobulin Thromb Haemostas 1978; 39: 22-31
15 Kluft C, Los N. Demonstration of two forms of α₂-antiplasmin in plasma by modified crossed immunoelectrophoresis. Thromb Res 1981; 21: 65-71
16 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. J Biol Chem 1982; 257: 2912-2919
17 Neumeier D, Prellwitz W, Knedel M. Infarct size estimation from serial analyses of creatine kinase and isoenzyme activity. In: Lang H. (ed.) Creatine Kinase Isoenzymes. Pathophysiology and Clinical Application Springer-Verlag; New York: 1981. pp 155-156
18 Morgan WT, Koskelo P, Koenig H, Conway TP. Human histidine- rich glycoprotein. II. Serum levels in adults, pregnant women and neonates. Proc Soc Exp Biol Med 1978; 158: 647-651
19 Jespersen J, Kluft C. Individual levels of plasma histidine-rich glycoprotein (HRG) during the normal menstrual cycle and in women on oral contraceptives low in oestrogen. Scand J Clin Lab Invest 1982; 42: 563-566
20 Lijnen HR, Jacobs G, Collen D. Histidine-rich glycoprotein in a normal and a clinical population. Thromb Res 1981; 22: 519-523
21 Saito H, Goodnough LT, Boyle JM, Heimburger N. Reduced histidine-rich glycoprotein levels in plasma of patients with advanced liver cirrhosis. JAMA 1982; 73: 179-182
22 Jespersen J. Sequential study of plasma euglobulipn fibrinolytic activity during the normal menstrual cycle and in women on oral contraceptives low in estrogen. Gynecol Obstet Invest 1983; 15: 266-274
23 Jespersen J, Sidelmann J. Individual levels of plasma α₂-antiplasmin and α₂-macroglobulin during the normal menstrual cycle and in women on oral contraceptives low in oestrogen. Thromb Haemostas 1983; 50: 581-585
24 Van Oss CJ, Bronson PM, Border JR. Changes in the serum alpha glycoprotein distribution in trauma patients. J Trauma 1975; 15: 451-455
25 Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G. Serum concentration of human alpha₂HS glycoprotein during the inflammatory process. J Clin Invest 1979; 64: 1118-1129
26 Lijnen HR, DeCock F, Collen D. Turnover of human histidine-rich glycoprotein in healthy subjects and during thrombolytic therapy. Thromb Res 1981; 23: 121-131